NCT05972135 2026-04-22
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
Clinical Trials
15 trialsNCT07107529 2026-04-15
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Recruiting
NCT06550895 2026-04-14
MonumenTAL-8
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04634552 2026-04-13
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06500884 2026-04-13
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06577025 2026-04-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT06353022 2026-03-17
IFm2022-01
Nantes University Hospital
Phase 2 Active not recruiting
NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT06066346 2026-03-04
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06100237 2026-02-23
REVIVE
University of Miami
Phase 2 Recruiting
NCT05695508 2025-12-24
HD10/DSMMXX
University of Heidelberg Medical Center
Phase 2 Recruiting
NCT06827860 2025-12-18
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT06993675 2025-08-29
ROTATE
Yale University
Phase 2 Recruiting
NCT06461988 2025-08-24
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Stanford University
Phase 2 Recruiting
NCT06505369 2024-07-17
TALTEC
North Estonia Medical Centre
Phase 2 Recruiting